Live
- RG Kar tragedy: CFSL reports suggest further probe to find whether rape & murder committed by only one or others involved
- PM Modi takes stock of 8 big infra projects worth Rs 1 lakh crore
- 98.5 pc land records digitised in rural areas, modernisation drive extended to 2026: Centre
- AP Sankranti Holidays 2025: Government Confirms Dates and Duration Amid Rumors
- I Must Have Been an Actor in My Past Life: Muralidhar Goud on His Passion for Cinema
- India's banking sector in robust health as NPAs fall and profits shoot up: Finance Ministry
- TG Indiramma Housing Scheme Delays: 8 Key Reasons Behind the Slow Progress of Indiramma House Survey
- Mangaluru Gears Up for Kambala
- Centre keen to promote traditional crop varieties for climate-resilient agriculture
- Activist Harassed and Attacked While Documenting Elephant’s Ordeal at Tamil Nadu Temple
Hyderabad based Dr Reddy's Laboratories launches Sorafenib tablets in UK market
Highlights
Dr Reddy's Laboratories on Tuesday said it has launched Sorafenib tablets, used in the treatment of various cancers, in the US market after getting approval from the US Food and Drug Administration.
Dr Reddy's Laboratories on Tuesday said it has launched Sorafenib tablets, used in the treatment of various cancers, in the US market after getting approval from the US Food and Drug Administration (USFDA).
"We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients," Dr Reddy's Laboratories Inc North America Generics CEO Marc Kikuchi said in a statement.
Dr Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120 and are used in the treatment of liver, kidney and thyroid cancer. The company's product is a therapeutic generic equivalent of Bayer HealthCare Pharmaceuticals Inc's Nexavar tablets.
Next Story
ADVERTISEMENT
